We are live on ! Find out more
BNTX icon

BioNTech

265 hedge funds and large institutions have $5.01B invested in BioNTech in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 75 increasing their positions, 100 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital inflows, than outflows

Capital inflows: $1.19B | Capital outflows: $627M

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

1.53% more ownership

Funds ownership: 13.77% → 15.31% (+1.5%)

10% less funds holding

Funds holding: 293 → 265 (-28)

25% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 100

32% less call options, than puts

Call options by funds: $282M | Put options by funds: $415M

49% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 49

Holders
265
Holders Change
-28
Holders Change %
-9.56%
% of All Funds
4.54%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.15%
New
25
Increased
75
Reduced
100
Closed
49
Calls
$282M
Puts
$415M
Net Calls
-$133M
Net Calls Change
+$118M

BNTX Hedge Fund Activity: Q3 2022 in Review

265 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q3 2022, worth a combined $5.01B — up 0.46% from $4.99B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of BNTX and 25 opened new positions — a net loss of 24 holders — while 100 trimmed existing stakes and 75 added.

The largest buyer was Temasek Holdings, adding an estimated $587M. The largest seller was T. Rowe Price Associates, cutting an estimated $90.4M.

  • 265 institutional investors held BioNTech (BNTX) as of Q3 2022, down from 293 in Q2 2022.
  • Funds reported $5.01B of BioNTech stock for Q3 2022, up 0.46% quarter-over-quarter.
  • 25 funds opened new BioNTech positions in Q3 2022 and 49 closed out, a net change of -24 holders.
  • The largest BioNTech buyer in Q3 2022 was Temasek Holdings, an estimated $587M added.
  • The largest BioNTech seller in Q3 2022 was T. Rowe Price Associates, an estimated $90.4M sold.

Based on aggregated 13F filings for Q3 2022.